Cybin Inc. has announced that the first study visit has been conducted in its feasibility study evaluating a quantitative neuroimaging technology to measure ketamine’s effects on cerebral cortex haemodynamics.
With the real-time quantification of brain activity during the psychedelic experience as a major barrier in psychedelic research, Cybin has embarked on a unique partnership with technology company Kernel.
Kernel’s neuroimaging technology – named Flow – is the first-ever commercially scalable time-domain functional, near-infrared spectroscopy system that enables the quantification of what was previously subjective self-reporting, CEO Doug Drysdale recently told Psychedelic Health.
Drysdale commented: “The commencement of the Kernel feasibility study marks a truly exciting moment, not only for Cybin and Kernel, but also for the entire field of psychedelic drug development.
“To this point, studies have had to rely on subjective patient reporting. By deploying the innovative Flow technology, this is the first time any company has had the ability to collect and quantify longitudinal brain activity before, during and after a psychedelic experience.
“We are specifically encouraged by this scientific advancement as it has the potential for Cybin to collect real-time quantitative data for our promising psychedelic-based therapies.
“These data will support the company’s leading research position as we move our important treatment options through regulatory discussions and late-stage clinical development.”
Using the Kernel Flow technology, Cybin is hoping to see real-time brain activity data before, during and after a patient’s treatment.
Founder and CEO of Kernel, Bryan Johnson, commented: “Kernel Flow is a groundbreaking neuroimaging technology that enables rigorous characterisation and quantification of physiological processes in the human brain.
“Our collaboration with Cybin has the potential to significantly enhance the research evaluating the potential positive effects of psychedelic therapies on the brain to improve mental wellness.”
Cybin also recently announced that it will be exploring the possibility that its psilocybin analogue – CYB003 – could be a potential treatment for major depressive disorder.
[activecampaign form=52]
